Monoclonal antibody for resisting cryptosphere capsular polysaccharide as well as encoding gene, expression and application thereof
Through anti-cryptosphere capsular polysaccharide monoclonal antibodies and magnetic microparticle chemiluminescence methods, the sensitivity and specificity of existing cryptococcal infection diagnosis methods are solved, and the detection of cryptococcal infection is achieved with high sensitivity and specificity, which is suitable for early diagnosis. .
Patent Information
- Application Number
- CN202411065715.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
The existing diagnostic methods for Cryptococcus infection have low sensitivity and poor specificity, which are prone to false positive results, and are complex in operation, making it difficult to achieve early accurate diagnosis.
Develop an anti-cryptosphere capsular polysaccharide monoclonal antibody and its encoding gene, express and prepare antibodies through recombinant vectors, combine with magnetic microparticle chemiluminescence method, and design a magnetic microsaccharide magnetic microsaccharide chemiluminescence detection kit to achieve high sensitivity, Tests with good specificity.
This method can effectively avoid false positive results, provide more accurate detection of cryptococci infection, is suitable for early diagnosis, and is characterized by high sensitivity, specificity and ease of operation.
Smart Images

Figure CN118978591A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and relates to an antibody and an application thereof, in particular to an anti-cryptococcal capsular polysaccharide monoclonal antibody, a coding gene thereof, and expression and application thereof. Background Art
[0002] Cryptococcus is a fungus widely found in nature, including variants such as Cryptococcus Neoformans and Cryptococcus gattii. Its infection mainly occurs in people with low immunity, such as AIDS patients, patients after organ transplantation, or patients who use glucocorticoids for a long time. Cryptococcus mainly enters the human body through the respiratory tract, and can also enter the body through the skin or digestive tract. When the body's resistance is low or immune deficiency occurs, it can cause disease, mainly invading the central nervous system and causing cryptococcal meningitis. Cryptococcal meningitis is the main cause of death from cryptococcal disease. About 1 million cases of cryptococcal disease are reported worldwide each year, and about 625,000 people die. Cryptococcus can also cause chronic fungal disease in the lungs, and the incidence of this disease has been on the rise in recent years.
[0003] Cryptococcal capsule is an important virulence factor, and its main components are glucuronoxylomannan (GXM), galactose xylomannan (GalXM) and a small amount of mannoprotein (MP), of which GXM accounts for more than 90% of the polysaccharide components. Cryptococcal virulence factors can interfere with the host's protective immune response, including the defense of antigen-presenting cells of the bone marrow lineage of dendritic cells, macrophages, and monocyte precursors. After cryptococcal infection, a large amount of capsular polysaccharides (i.e., glucuronoxylomannan) can be formed in the body and released into the blood. Cryptococcal infection can be diagnosed early by detecting capsular polysaccharide antigens.
[0004] In recent years, with the clinical application of broad-spectrum antibiotics, glucocorticoids, anti-tumor drugs, and immunosuppressants, the development of various invasive diagnostic and treatment technologies, and the increasing number of people infected with HIV-1, the incidence of deep fungal infections has also increased year by year. Cryptococcus is one of the common pathogens of deep fungal infections in clinical practice. The cryptococci that cause human infections are mainly Cryptococcus neoformans and Cryptococcus gattii, which mainly cause cryptococcal meningitis and pulmonary cryptococcosis. Capsular polysaccharides are the cell wall extracellular structures of cryptococci, which are important toxic factors and biomarkers of cryptococcal infection. Therefore, the detection of cryptococcal capsular polysaccharides is of great significance for the auxiliary diagnosis of clinical cryptococcal infection.
[0005] At present, the main methods for detecting cryptococci in clinical practice are culture, ink staining microscopy, colloidal gold method, etc. Among them, the culture method is the "gold standard" for detecting cryptococci. The detection takes 3-10 days, has low sensitivity, is time-consuming, and is very likely to cause delayed treatment; cerebrospinal fluid ink smear can diagnose cryptococcal meningitis early and quickly, but the specificity and sensitivity of the diagnosis depend on the technical level of the examiner, and the detection rate is low; there is non-specific interference in the detection of cryptococcal capsular polysaccharide antigens by latex agglutination method, and rheumatoid factor and macroglobulin in the serum of patients with rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis and tuberculosis can lead to false positive results, and certain spore-trichol and trichosporon infections can also cause false positives; molecular biological detection is based on the PCR method to detect fungal nucleic acid DNA. Due to the thick cell wall of the fungus, it is difficult to break it to release DNA, so the PCR method has a low positive rate for detecting fungal infection, and is currently still in the research and development stage. The limitations of the above methods have made it very difficult to diagnose cryptococcal infection in the clinic at present. Therefore, there is a great need in clinical practice for a detection method with high sensitivity, good specificity, low interference and simple operation, which is suitable for the early diagnosis of cryptococcal infection. Summary of the invention
[0006] In view of the above problems, the present invention provides an anti-cryptococcal capsular polysaccharide monoclonal antibody, its encoding gene, and its expression and application.
[0007] The technical solution adopted by the present invention to achieve its purpose is as follows:
[0008] An anti-cryptococcosis capsular polysaccharide monoclonal antibody, comprising a light chain variable region determining cluster complementary region and a heavy chain variable region determining cluster complementary region;
[0009] The amino acid sequence of the complementary region of the light chain variable region determining cluster is selected from the amino acid sequence of the CDRs of the following group: VL-CDR1 shown in SEQ ID NO: 1, VL-CDR2 shown in SEQ ID NO: 2, and VL-CDR3 shown in SEQ ID NO: 3;
[0010] The amino acid sequence of the heavy chain variable region complementary region determining cluster is selected from the following group of CDR amino acid sequences: VH-CDR1 shown in SEQ ID NO: 4, VH-CDR2 shown in SEQ ID NO: 5 and VH-CDR3 shown in SEQ ID NO: 6.
[0011] Furthermore, the amino acid sequence of the complementary region of the light chain variable region determining cluster of the anti-cryptococcal capsular polysaccharide monoclonal antibody is SEQ ID NO: 7; the amino acid sequence of the complementary region of the heavy chain variable region determining cluster is SEQ ID NO: 8.
[0012] A gene encoding the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody, wherein the nucleotide sequence of the complementary region of the light chain variable region determining cluster is SEQ ID NO: 9, and the nucleotide sequence of the complementary region of the heavy chain variable region determining cluster is SEQ ID NO: 10.
[0013] A recombinant vector comprising the gene of the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody;
[0014] The recombinant vector is a eukaryotic recombinant expression plasmid pCMVp-NEO-BAN-Anti-GXM containing the gene of the variable region of the anti-cryptococcal capsular polysaccharide monoclonal antibody.
[0015] A recombinant expression cell comprising the gene of the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody;
[0016] The recombinant expression cells are Chinese hamster ovary cells that recombinantly express anti-cryptococcal capsular polysaccharide monoclonal antibodies;
[0017] The recombinant vector and the recombinant expression cell obtained after introducing the recombinant vector into the cell belong to the protection scope of the present invention. The recombinant vector refers to all recombinant vectors (also called recombinant plasmids) containing the gene of the above-mentioned cryptococcal capsular polysaccharide monoclonal antibody, and the recombinant expression cell refers to all recombinant expression cells containing the gene of the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody, and is not limited to the eukaryotic recombinant expression plasmid pCMVp-NEO-BAN-Anti-GXM containing the gene of the variable region of the anti-cryptococcal capsular polysaccharide monoclonal antibody and the recombinant expression Chinese hamster ovary cell of the anti-cryptococcal capsular polysaccharide monoclonal antibody pointed out in the present invention. It should be understood that the recombinant vector involved in the technical scheme claimed for protection of the present invention is a recombinant vector obtained by inserting the gene of the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody into any expression vector (also called expression plasmid) that can be purchased by a person skilled in the art; the recombinant cell is a recombinant expression cell obtained by introducing the above-mentioned recombinant vector into any expression cell.
[0018] A cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit contains the above-mentioned anti-cryptococcal capsular polysaccharide monoclonal antibody.
[0019] Furthermore, the cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit contains the anti-cryptococcal capsular polysaccharide monoclonal antibody labeled with biotin.
[0020] Furthermore, the cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit also contains the anti-cryptococcal capsular polysaccharide monoclonal antibody labeled with a chemiluminescent group.
[0021] A method for detecting cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence uses the cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit and adopts magnetic microparticle chemiluminescence method for detection.
[0022] The beneficial effects of the present invention are:
[0023] The monoclonal antibody derived from anti-cryptococcal polysaccharide provided by the invention specifically binds to cryptococcal polysaccharide, has high antibody affinity, and does not cross-react with substances such as (1,3)-β-D glucan, Aspergillus galactomannan, Sporothrix, Trichosporon, Mycobacterium tuberculosis, etc. The cryptococcal polysaccharide magnetic particle chemiluminescence detection kit developed based on the antibody characteristics has high sensitivity, good specificity, wide quantitative detection range, fast detection speed, and can realize machine automation operation, especially can effectively avoid false positive detection results caused by rheumatoid factor, macroglobulin, hydroxyethyl starch, Sporothrix, Trichosporon, etc., provide more accurate detection information for clinical use, can meet the clinical requirements for early diagnosis of fungal infection, and has good clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is a process diagram of clone cell screening in Example 1 of the present invention.
[0025] Figure 2 This is a diagram showing the electrophoresis results of the Marker and purified monoclonal antibody IgG in Example 2 of the present invention.
[0026] Figure 3 This is a graph showing the results of the cross-reaction assay of the purified anti-cryptococcal capsular polysaccharide monoclonal antibody in Example 4 of the present invention with other substances interfering with the detection. DETAILED DESCRIPTION
[0027] The technical solutions in the embodiments of the present invention are described clearly and completely below. In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention can also be implemented in other ways different from those described herein, and those skilled in the art can make similar generalizations without violating the connotation of the present invention, so the present invention is not limited by the specific embodiments disclosed below.
[0028] Capsular polysaccharide: homemade. The process of making cryptococcal capsular polysaccharide is as follows: prepare YM broth liquid culture medium, sterilize at 121℃ for 30min, inoculate the cultured cryptococcal strain into the culture medium, and culture in a shake flask; sterilize at 121℃ for 30min, filter with a 0.22μm filter membrane, add an equal volume of ethanol to the filtrate for precipitation, wash with ethanol solution after centrifugation, and then re-dissolve with ultrapure water to obtain capsular polysaccharide;
[0029] Freund's complete adjuvant was purchased from Sigma-Aldrich, catalog number: F5881;
[0030] Freund's incomplete adjuvant was purchased from Sigma-Aldrich, catalog number: F5506;
[0031] The enzyme-labeled secondary antibody was HRP-labeled goat anti-mouse IgG, purchased from Jackson, USA, catalog number: 115-035-003;
[0032] TMB was purchased from Quanshijin Company, item number: HE111-01;
[0033] Chinese hamster ovary cells were purchased from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (cell number: 1101HAM-PUMC000116);
[0034] Streptavidin magnetic particles are Dynabeads TM M-270 streptavidin, purchased from Thermo Fisher, catalog number 65305;
[0035] Sulfo-NHS-LC-Biotin was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., CAS No.: 191671-46-2, Product No.: S288926;
[0036] NSP-SA-NHS was purchased from Suzhou Meilun Biotechnology Co., Ltd., CAS number: 199293-83-9, product number: MB3332.
[0037] Example 1 Preparation of hybridoma cells
[0038] 1) Animal immunization
[0039] Monoclonal antibodies can be obtained by using common immunological techniques, using capsular polysaccharides as antigens, immunizing animals, and then using cells of the immunized animals to prepare hybridoma cells. The type of immunized animals used in the preparation of hybridoma cells is not particularly limited, such as mice, rats, hamsters, rabbits, etc., and BALB / c mice are used as immunized animals in this embodiment. When the antigen is used for animal immunization, it is better to use an adjuvant in combination, and the adjuvant can improve the immune response of the immunized animal to the antigen. The type of adjuvant is not particularly limited, for example, Freund's complete adjuvant, Freund's incomplete adjuvant, pertussis vaccine, aluminum adjuvant, etc. can be used, wherein Freund's complete adjuvant is used in the first immunization in this embodiment, and Freund's incomplete adjuvant is used in the second and subsequent immunizations.
[0040] Take equal volumes of capsular polysaccharide and Freund's complete adjuvant and mix them fully emulsified as the primary immunization reagent;
[0041] BALB / c mice aged 6 to 8 weeks (mouse A, mouse B and mouse C) were injected subcutaneously at multiple points with the primary immunization reagent. The dose of the primary immunization reagent was equivalent to 50 μg of capsular polysaccharide per mouse. Immunization was performed every 2 weeks thereafter. For the second immunization, equal volumes of mixed and fully emulsified capsular polysaccharide and Freund's incomplete adjuvant were used for intraperitoneal injection. The immunization dose was equivalent to 50 μg of capsular polysaccharide per mouse. Seven days after the fifth immunization, the antibody titer was determined by ELISA method using the medial canthus venous blood of the mice. The specific antibody titer determination method (ELISA method) is as follows:
[0042] 1) Antigen coating: Dilute the capsular polysaccharide to 1 μg / mL with coating buffer (1.059 g Na2CO3, 2.93 g NaHCO3, add ultrapure water to 1000 mL, adjust pH to 9.6) and add 0.1 mL to each well of the ELISA plate, overnight at 4°C. The next day, discard the liquid in the wells and wash three times with PBST washing buffer (0.2 g KH2PO4, 2.9 g Na2HPO4·12H2O, 8.0 g NaCl, 0.2 g KCl, 0.5 mL Tween-20, add ultrapure water to 100 mL, adjust pH to 7.4). Add 300 μL of PBST washing buffer to each well during each wash (if not specified below, the reagents and amounts used for washing are the same as this time), and pat dry.
[0043] 2) Blocking: Add 0.1 mL of PBST washing buffer containing 3% BSA to each well, incubate at 37°C for 1 hour, then wash 3 times with PBST washing buffer, pat dry, and obtain the ELISA plate to be tested.
[0044] 3) Add the mouse serum samples to be tested: take the medial canthal venous blood of different mice, centrifuge at 2000 rpm for 5 min, and then take the serum. Dilute it 1000 times, 10,000 times, 50,000 times, 100,000 times, 500,000 times, 1 million times, 1.5 million times and 2 million times with 0.1 mol / L PBS to obtain immune mouse serum of different dilution multiples;
[0045] Take 100 μL of immune mouse serum with different dilution multiples and add it to the wells of the ELISA plate to be tested. At the same time, use the serum of non-immunized mice as a negative control and 0.1 mol / L PBS as a blank control. Incubate at 37°C for 1 h, discard the liquid in the wells, wash three times with PBST washing buffer, and pat dry.
[0046] 4) Add enzyme-labeled secondary antibody: first dilute the enzyme-labeled secondary antibody to the working concentration using dilution buffer (0.1 g of BSA is added to PBS buffer and the volume is fixed to 100 mL), i.e., dilute 10,000 times to obtain enzyme-labeled secondary antibody dilution solution;
[0047] 100 μL of enzyme-labeled secondary antibody dilution was added to each well, incubated at 37°C for 1 h, washed with PBST washing buffer, and patted dry.
[0048] 5) Color development: Add 100 μL of the color development substrate TMB to each well and incubate at 37°C for 15 min.
[0049] 6) Termination of reaction: Add 100 μL of stop solution (1 mol / L HCl) to each well to terminate the reaction.
[0050] 7) Determination of results: Measure the absorbance value (A450nm) of each well after adjusting the blank control well to zero at 450nm on the microplate reader. When the ratio of the A450nm value of the sample to be tested to the A450nm value of the negative control is greater than 2.1, and the antibody detection OD value is required to be ≥0.5 and the negative control is ≥0.1, the maximum dilution of the antibody at this time is the antibody titer. The specific antibody titer determination results are shown in the table below:
[0051] Table 1 Antibody titer of mice after five immunizations (A 450nm )
[0052]
[0053] As can be seen from Table 1, the antibody titer of mouse A reached more than 1:1.5 million, which was the best, and this mouse was selected for subsequent experiments.
[0054] 2) Hybridoma cell preparation
[0055] 1) Preparation of myeloma SP2 / 0 cell suspension
[0056] Two weeks before fusion, mouse myeloma cells (SP2 / 0 cells) were routinely resuscitated and inoculated into culture medium (RPMI1640 culture medium containing 10-20% fetal bovine serum, supplemented with 100 IU / mL penicillin and 100 μg / mL streptomycin), and cultured in a 5% CO2 incubator at 37°C. 48-36 hours before fusion, complete culture medium (RPMI1640 culture medium containing 20% fetal bovine serum) was used and cultured in a 37°C, 5% CO2 incubator for expansion.
[0057] On the day of fusion, the cells were gently blown off the flask wall with a pipette, collected in a 50 mL centrifuge tube, centrifuged at 1500 rpm for 6 min, the supernatant was discarded, and 30 mL of incomplete culture medium was added to the obtained tumor cell pellet [the incomplete culture medium was prepared by adding 2% NaHCO3, 3% 4-hydroxyethylpiperazineethanesulfonic acid (Hepes), 0.011% sodium pyruvate to RPMI1640 culture medium, and adjusting the pH to 6.8-7.0 with 1 mol / L HCl], centrifuged again at 1500 rpm for 6 min, and then washed once with PBST washing buffer, observed the cells under a microscope, and selected cells of equal size, roundness, transparency, and good activity as SP2 / 0 cells, and collected SP2 / 0 cells to make the number of SP2 / 0 cells reach 2×10 7 cell, and then resuspend the SP2 / 0 cells in 10 mL of incomplete culture medium and mix well to obtain myeloma SP2 / 0 cell suspension.
[0058] 2) Preparation of immune spleen cell suspension:
[0059] Three days before cell fusion, mice A were given a booster immunization by tail vein injection using an equal volume of mixed and fully emulsified capsular polysaccharide and Freund's incomplete adjuvant. The booster immunization dose was equivalent to 10 μg of capsular polysaccharide per mouse. Three days later, the eyeballs were removed for bleeding, and the serum was separated for antibody detection. The mice were killed by pulling the neck, soaked in 75% alcohol for 5 minutes, and then placed in a clean bench. The abdomen was opened with aseptic surgery, the spleen was removed, and it was rinsed in a plate containing 8 mL of incomplete culture medium, and the surrounding connective tissue was carefully peeled off to obtain the processed spleen.
[0060] The treated spleen was transferred to another dish containing 5 mL of incomplete culture medium and placed on a 200-mesh stainless steel net. The treated spleen was cut into small pieces with scissors, then squeezed and ground with the inner core of a syringe, and the steel net was gently rinsed with the incomplete culture medium in the dish to squeeze all the spleen cells into the liquid. The resulting spleen cell solution was transferred to a 50 mL centrifuge tube, and incomplete culture medium was added to 30 mL and mixed. The solution was centrifuged at 1500 rpm for 6 min, and the supernatant was discarded. The solution was then added to 30 mL of incomplete culture medium and mixed. The solution was centrifuged at 1500 rpm for 6 min and washed once again. The resulting precipitated cells were resuspended in incomplete culture medium to 10 mL and mixed to obtain a spleen cell suspension (generally 1 to 2.5 × 10 cells / mouse per mouse) 8 The spleen cells were stained with trypan blue and examined under a phase contrast microscope. The qualified rate was when the number of viable cells was higher than 80%).
[0061] 3) Cell fusion:
[0062] Pipette 1×10 8 The spleen cell suspension contained 2×10 7Add the myeloma SP2 / 0 cell suspension of 10 myeloma cells to a 50mL centrifuge tube, add incomplete culture medium to 30mL, mix thoroughly, centrifuge at 1200rpm for 6min at room temperature, discard the supernatant, tap the bottom of the tube gently to make the precipitated cells loose and uniform into a paste, place it in a 37℃ water bath, drip 1mL of PEG1650 along the rotating tube wall, let it stand for 90s, then take the centrifuge tube out of the water bath, centrifuge at 1000rpm for 6min, discard the supernatant, add 10mL of HAT culture medium to the obtained precipitate, gently blow and aspirate the precipitated cells to suspend and mix them, and obtain a fusion cell suspension;
[0063] The fused cell suspension was added to a 96-well culture plate containing HAT culture medium, 2 drops per well, and cultured in a 37°C incubator for 7 days. After 7 days, the culture medium was replaced, and 1 / 2 to 2 / 3 of the culture medium was aspirated when the medium was replaced (2 / 3 of the culture medium was aspirated in this embodiment), and an equal amount of HT culture medium was added, and cultured again for 7 days. After 14 days, the culture medium was replaced again, and 1 / 2 to 2 / 3 of the culture medium was aspirated when the medium was replaced (2 / 3 of the culture medium was aspirated in this embodiment), and an equal amount of complete culture medium (RPMI1640 culture medium containing 20% fetal bovine serum) was added to obtain a hybridoma cell suspension.
[0064] 4) Screening and detection of hybridoma cells
[0065] The antibody titer of the hybridoma cell suspension was detected by ELISA (see Example 1 for specific operating steps), with complete culture medium as a negative control and 0.1 mol / L PBS as a blank control. If the ratio of the A450nm value of the hybridoma cell suspension to the A450nm value of the negative control was greater than 2.1, the antibody titer of the hybridoma cell suspension was positive.
[0066] 5) Clonal culture
[0067] The antibody titer-positive hybridoma cell suspension was expanded from a 96-well plate to a 24-well plate for 3-5 days, and the hybridoma cells to be cloned in the 24-well plate were repeatedly blown and evenly mixed with a pipette, and 20 μL of the hybridoma cell suspension to be cloned was added to 1 mL of PBS with a concentration of 0.1 mol / L, and diluted 50 times to obtain a diluted cell suspension;
[0068] The diluted cell suspension was counted using a cell counting plate. The calculation formula is as follows: number of cells in the cell suspension / mL = (total number of cells in 4 large grids on the counting plate / 4) × 10000 × 50 (dilution factor). The number of cells is 3 × 10 6 / mL.
[0069] According to the above cell count concentration, a cell suspension containing 230 live cells was suspended in 4.6 mL of complete culture medium (RPMI1640 culture medium containing 20% fetal bovine serum), and the obtained live cell solution was inoculated in a 96-well culture plate, 0.1 mL of live cell solution per well, for a total of 36 wells (recorded as the first group). To the remaining 1 mL of live cell solution, 4 mL of complete culture medium (RPMI1640 culture medium containing 20% fetal bovine serum) was added to obtain a total of 5 mL of cell solution, and then the cell solution was inoculated in the remaining 36 wells, 0.1 mL of cell solution per well (recorded as the second group). To the remaining 1.4 mL of cell solution, 1.4 mL of complete culture medium (RPMI1640 culture medium containing 20% fetal bovine serum) was added to inoculate the remaining 24 wells, 0.1 mL per well (recorded as the third group). In this way, cloning was performed at three different cell concentrations: the first group had 36 wells with an average of 5 cells per well, the second group had 36 wells with an average of 1 cell per well, and the third group had 24 wells with an average of 0.5 cells per well.
[0070] The 96-well culture plate was placed in a 37°C, 5% CO2 incubator for 5 days. After 5 days, the cell clone growth was observed under an inverted microscope, the medium was changed, and the antibody secretion was detected by ELISA. The positive monoclonal wells were cloned again according to the above cloning method. The monoclonal wells that were positive for two clones were selected and transferred to a 24-well plate, and then transferred to a culture flask for expansion and cryopreservation. The specific clone cell screening process is shown in Figure 1 .
[0071] 6) Cryopreservation of hybridoma cells
[0072] Observe the state of cells expanded in the cell culture flask, pour off the supernatant culture medium of hybridoma cells in the logarithmic growth phase, add 1 mL of incomplete culture medium with a pipette, add 0.8 mL of fetal bovine serum and 0.2 mL of dimethyl sulfoxide, mix well, count the cells, and dispense into cryopreservation tubes. The number of cells added to each cryopreservation tube should be no less than 1×10 6 The cryotubes were precooled at 4°C for 30 minutes, placed at -20°C for 2 hours, then moved to a -70°C low-temperature refrigerator overnight, and finally stored in liquid nitrogen.
[0073] Example 2 Preparation of anti-cryptococcal capsular polysaccharide monoclonal antibodies
[0074] The hybridoma cells that are positive in the screening are collected for cloning, and the antibodies secreted by them are collected, which are anti-cryptococcosis capsular polysaccharide monoclonal antibodies. The anti-cryptococcosis capsular polysaccharide monoclonal antibodies are collected, and the gene sequence of the variable region of the anti-cryptococcosis capsular polysaccharide monoclonal antibodies is determined:
[0075] The amino acid sequence of the complementary region of the light chain variable region determining cluster is composed of VL-CDR1 shown in SEQ ID NO: 1: VGTDLSGDQMKPMASISCRSS; VL-CDR2 shown in SEQ ID NO: 2: PKGSQSDCRILLCYEV and VL-CDR3 shown in SEQ ID NO: 3: YWSSDGRSTVHQLKSDWTFH;
[0076] The specific light chain CDR amino acid sequence is shown in SEQ ID NO: 7:
[0077] SEQ ID NO: 7 (57Aa):
[0078] VGTDLSGDQMKPMASISCRSSPKGSQSDCRILLCYEVYWSSDGRST
[0079] VHQLKSDWTFH
[0080] Val Gly Thr Asp Leu Ser Gly Asp Gln Met Lys Pro Met Ala Ser IleSerCys Arg Ser Ser Pro Lys Gly Ser Gln Ser Asp Cys Arg Ile Leu Leu Cys TyrGluVal Tyr Trp Ser Ser Asp Gly Arg Ser Thr Val His Gln Leu Lys Ser Asp TrpThrPhe His;
[0081] The nucleotide sequence of the light chain variable region of the nucleic acid molecule encoding the cryptococcal capsular polysaccharide monoclonal antibody is shown in SEQ ID NO: 9:
[0082] SEQ ID NO: 9 (171 bp):
[0083] GTTGGTACTGATTTATCTGGCGACCAAATGAAACCTATGGCTTCCATTTCATGTCGTTCGAGTCCCAAGGGAAGCCAGTCTGATTGCCGCATCTTGCTTTGTTATGAAGTCTACTGGTCCTCAGACGGGCGATCGACCGTACATCAACTCAAAAGTGATTGGACATTTCAC.
[0084] The amino acid sequence of the heavy chain variable region complementary determining region is composed of VH-CDR1: DVVGLTTQTPLGSLPVSLGDQVS as shown in SEQ ID NO: 4, VH-CDR2: LVHSNGTDTYSLHWYLSQKPGQSPKV as shown in SEQ ID NO: 5, and VH-CDR3: GSGTKDFTLKISRTVEAEDLGVYFCSQGTHLPWT as shown in SEQ ID NO: 6;
[0085] The specific heavy chain CDR amino acid sequence is shown in SEQ ID NO: 8:
[0086] SEQ ID NO: 8 (83Aa):
[0087] DVVGLTTQTPLGSLPVSLGDQVSLVHSNGTDTYSLHWYLSQKPGQ
[0088] SPKVGSGTKDFTLKISRTVEAEDLGVYFCSQGTHLPWT
[0089] Asp Val Val Gly Leu Thr Thr Gln Thr Pro Leu Gly Ser Leu Pro ValSerLeu Gly Asp Gln Val Ser Leu Val His Ser Asn Gly Thr Asp Thr Tyr Ser LeuHisTrp Tyr Leu Ser Gln Lys Pro Gly Gln Ser Pro Lys Val Gly Ser Gly Thr LysAspPhe Thr Leu Lys Ile Ser Arg Thr Val Glu Ala Glu Asp Leu Gly Val TyrPhe CysSer Gln Gly Thr His Leu Pro Trp Thr;
[0090] The nucleotide sequence of the heavy chain variable region of the nucleic acid molecule encoding the cryptococcal capsular polysaccharide monoclonal antibody is shown in SEQ ID NO: 10:
[0091] SEQ ID NO: 10 (249 bp):
[0092] GATGTTGTCGGTTTAACTACCCAAACACCTTTGGGCTCTCTTCCCGTATCCCTCGGAGACCAGGTGTCACTAGTTCATTCGAATGGGACGGATACTTATAGTCTGCACTGGTACTTAAGCCAAAAACCAGGTCAGTCTCCGAAGGTCGGCTCCGGAACCAAAGACTTTACATTGAAGATTTCACGTACGGTAGAAGCTGAGGATCTTGGGGTGTATTTCTGTTCGCAAGGTACTCATCTC CCTTGGACC.
[0093] Sangon Biotech (Shanghai) Co., Ltd. was commissioned to construct a eukaryotic recombinant expression plasmid pCMVp-NEO-BAN-Anti-GXM containing the variable region gene of the anti-cryptococcal capsular polysaccharide monoclonal antibody.
[0094] The eukaryotic recombinant expression plasmid pCMVp-NEO-BAN-Anti-GXM was introduced into Chinese hamster ovary cells (CHO cells) to obtain recombinant expression Chinese hamster ovary cells of anti-cryptococcal capsular polysaccharide monoclonal antibodies.
[0095] The recombinant Chinese hamster ovary cells expressing anti-cryptococcal capsular polysaccharide monoclonal antibody were inoculated into DMEM medium containing 10% fetal bovine serum, and 1 mmol / L isopropyl-β-D-thiogalactoside (IPTG) was added as an inducer. The expression was induced for 48 hours at 37°C and 5% CO2, and the cell culture supernatant (expression product) was collected.
[0096] The saturated ammonium sulfate method was used to prepare a crude extract of monoclonal antibody IgG: 5 mL of cell culture supernatant was taken, and 5 mL of normal saline and 10 mL of saturated ammonium sulfate aqueous solution were added respectively. After being placed at 4°C overnight, the mixture was centrifuged at 3000 rpm for 30 min, and the supernatant was discarded. 5 mL of normal saline and 5 mL of saturated ammonium sulfate aqueous solution were added to the remaining precipitate, which was placed at 4°C overnight, and then centrifuged at 3000 rpm for 30 min. The supernatant was discarded. 5 mL of normal saline and 2.5 mL of saturated ammonium sulfate aqueous solution were added to the obtained precipitate again, which was placed at 4°C overnight, and centrifuged at 3000 rpm for 30 min. The supernatant was discarded. The obtained precipitate was dissolved in 2 mL of normal saline and dialyzed against the normal saline for 18 hours to obtain a crude extract of monoclonal antibody IgG.
[0097] Protein A gel affinity chromatography to purify monoclonal antibody IgG: 1 mL of Protein A was taken, loaded into the column and balanced with 20 mmol / L sodium phosphate buffer (mix 20 mmol / L Na2PO3 and 20 mmol / L NaH2PO3 in equal volumes, and adjusted to pH = 7.0), 5 mL of the crude extract of monoclonal antibody IgG was repeatedly applied to the column 20 times at 4°C, the column was fully eluted with 20 mmol / L sodium phosphate buffer until the OD280 was approximately equal to 0 as determined by spectrophotometry, and then 0.1 mol / L glycine-hydrochloric acid buffer (pH = 2.7) was used for elution, 500 μL each time, and the eluent was neutralized with 20 μL of 1.0 mol / L Tris-HCl buffer (pH = 9.0), the obtained antibody eluate was used to determine the protein content by the CBG method, the protein peak was collected, and then it was fully dialyzed with 0.01 mol / L PBS buffer (pH = 7.4) to obtain purified monoclonal antibody IgG.
[0098] The marker and purified monoclonal antibody IgG were determined by SDS-PAGE electrophoresis. Figure 2 It can be seen that the molecular weights of the two protein bands are about 54kD and 25kD according to the protein molecular weight regression equation, which is consistent with the molecular weights of IgG heavy chain and light chain reported in the literature. Therefore, the purified monoclonal antibody IgG is the purified anti-cryptococcal capsular polysaccharide monoclonal antibody.
[0099] Example 3 Determination of the titer of purified anti-cryptococcal capsular polysaccharide monoclonal antibodies
[0100] 1) Dilute the capsular polysaccharide to 1 μg / mL with coating buffer and add 0.1 mL to each well of the ELISA plate. Incubate at 4°C overnight. Discard the liquid in the wells the next day and wash three times with PBST washing buffer. Add 300 μL of PBST washing buffer to each well each time and pat dry.
[0101] 2) Add 0.1 mL of PBST washing buffer containing 3% BSA to each well, incubate at 37°C for 1 hour, then wash three times with PBST washing buffer, pat dry, and obtain the well plate for testing.
[0102] 3) diluting the purified anti-cryptococcal capsular polysaccharide monoclonal antibody with 0.1 mol / L PBS buffer by 10,000 times, 100,000 times, 500,000 times, 1 million times, 2 million times, 5 million times and 10 million times respectively to obtain antibody dilution solutions of different dilution multiples;
[0103] Take 100 μL of antibody dilutions with different dilution multiples and add them to the wells of the test plate. At the same time, use complete culture medium as a negative control and 0.1 mol / L PBS as a blank control. Incubate at 37°C for 1 hour, discard the liquid in the wells, wash three times with PBST washing buffer, and pat dry.
[0104] 4) Add 100 μL of enzyme-labeled secondary antibody dilution to each well, incubate at 37°C for 1 h, wash with PBST washing buffer, and pat dry.
[0105] 5) Add 100 μL of the chromogenic substrate TMB to each well and incubate at 37°C for 15 min.
[0106] 6) Add 100 μL of stop solution (1 mol / L HCl) to each well to terminate the reaction.
[0107] 7) After adjusting the blank control well to zero at 450nm on the microplate reader, measure the absorbance value (A450nm) of each well, and the results are shown in Table 2. When the ratio of the A450nm value of the sample to be tested to the A450nm value of the negative control is greater than 2.1, and the antibody detection OD value is ≥0.5, and the negative control is ≥0.1, the dilution multiple is the titer. It can be seen from Table 2 that the titer of the purified anti-cryptococcal capsular polysaccharide monoclonal antibody is above 1:5 million, and its affinity is very high.
[0108] Table 2 Antibody titer after purification (A450nm)
[0109]
[0110] Example 4 Specificity Identification of Purified Anti-Cryptococcus Capsular Polysaccharide Monoclonal Antibodies
[0111] The present invention is to obtain a monoclonal antibody that strongly binds only to the capsular polysaccharide, but rarely binds or even does not bind to other substances that interfere with the detection. After strict screening and monoclonalization of hybridoma cells, the anti-cryptococcal capsular polysaccharide monoclonal antibody purified after recombinant expression by genetic engineering technology was once again specifically identified. The specificity of the antibody can be measured by whether it has cross-reactivity with the analogs of cryptococcal capsular polysaccharide and the size of the cross-reaction. The specific operation and identification method is as follows:
[0112] 1) Dilute (1,3)-β-D glucan, Aspergillus galactomannan, Candida mannan, and hydroxyethyl starch to 10 μg / mL with coating buffer, add 0.1 mL to each well of the coated ELISA plate, and incubate at 4°C overnight. The next day, discard the liquid in the wells and wash three times with PBST washing buffer. Add 300 μL of PBST washing buffer to each well each time and pat dry.
[0113] 2) Add 0.1 mL of PBST washing buffer containing 3% BSA to each well, incubate at 37°C for 1 hour, then wash three times with PBST washing buffer and pat dry to obtain well plates containing different coated polysaccharides.
[0114] 3) Dilute the purified anti-cryptococcal capsular polysaccharide monoclonal antibody to a concentration of 1 μg / mL in 0.1 mol / L PBS buffer.
[0115] 4) Take 100 μL of purified antibody dilution and add it to the wells containing different coated polysaccharides, use complete culture medium as negative control and PBS as blank control, incubate at 37°C for 60 min, discard the liquid in the wells, wash 3 times with PBST washing buffer, add 100 μL of enzyme-labeled secondary antibody dilution to each well, incubate at 37°C for 1 h, wash with PBST washing buffer, and pat dry.
[0116] 5) Add 100 μL of the chromogenic substrate TMB to each well and incubate at 37°C for 15 min.
[0117] 6) Add 100 μL of stop solution (1 mol / L HCl) to each well to terminate the reaction.
[0118] 7) Use the microplate reader to zero the blank well at 450nm and measure the absorbance value (A450nm) of each well. Figure 3 It can be seen that the purified anti-cryptococcosis capsular polysaccharide monoclonal antibody had no cross reaction with (1,3)-β-D glucan, Aspergillus galactomannan, Candida mannan, and hydroxyethyl starch at a concentration of 1 μg / mL, indicating that the purified anti-cryptococcosis capsular polysaccharide monoclonal antibody has very good specificity and is less affected by other substances.
[0119] Example 5 Preparation and Application of Cryptococcus Capsular Polysaccharide Magnetic Microparticle Chemiluminescence Detection Kit
[0120] 1) Preparation of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0121] In this embodiment, purified anti-cryptococcosis capsular polysaccharide monoclonal antibody is used as capture antibody and / or detection antibody to prepare a cryptococcosis capsular polysaccharide magnetic particle chemiluminescent detection kit that can be used clinically. The main components of the kit include: purified anti-cryptococcosis capsular polysaccharide monoclonal antibody labeled with biotin, purified anti-cryptococcosis capsular polysaccharide monoclonal antibody labeled with chemiluminescent group [in this embodiment, purified anti-cryptococcosis capsular polysaccharide monoclonal antibody labeled with acridine sulfonamide is used, and it can also be labeled with at least one of acridine sulfonamide, acridine ester, ruthenium complex, luminol, (adamantane)-1,2-dioxyethane or alkaline phosphatase], streptavidin magnetic particles (Dynabeads TMM-270 streptavidin), low value calibrator [capsular polysaccharide concentration is 1 ng / mL], high value calibrator [capsular polysaccharide concentration is 50 ng / mL], low value quality control [capsular polysaccharide concentration is 0.5 ng / mL], high value quality control [capsular polysaccharide concentration is 50 ng / mL]; chemiluminescent excitation liquid A (0.1 mol / L HNO3, 1.32% H2O2), chemiluminescent excitation liquid B (0.35 mol / L NaOH) and PBST washing buffer.
[0122] Purified anti-cryptococcal polysaccharide monoclonal antibodies are coupled to a solid phase carrier, and the solid phase carrier is at least one of carboxylated magnetic particles and avidinized magnetic particles. In this embodiment, streptavidin magnetic particles are used as the solid phase carrier. The specific cryptococcal polysaccharide magnetic particle chemiluminescence detection kit is as follows:
[0123] 1) Preparation of biotin-labeled purified anti-cryptococcal capsular polysaccharide monoclonal antibody
[0124] Take 200 μg of capsular polysaccharide antibody and dilute it to 1 mg / mL with 0.02 mol / L PBS (pH=7.4) to obtain an antibody solution.
[0125] Take 1 mg of Sulfo-NHS-LC-Biotin (for biotin antibody labeling) and dissolve it in 100 μL of dimethyl sulfoxide, take 3 μL and add it to the antibody solution and mix it evenly, and react it at room temperature in the dark for 1 hour. After the reaction is completed, put the reaction product into a dialysis bag (exclusion MW: 8000), use 0.02 mol / L PBS (pH=7.4) as the dialysis solution, and dialyze it at 2-8°C for 24 hours (dialysis is performed at 4°C in this embodiment), add Proclin300 and 1% trehalose with a final concentration of 0.1% to the obtained dialysis product, and obtain the purified anti-cryptococcosis capsular polysaccharide monoclonal antibody labeled with biotin, seal it in the dark and place it at 2-8°C for standby use (dialysis is performed at 4°C in this embodiment). When used, the purified anti-cryptococcosis capsular polysaccharide monoclonal antibody labeled with biotin is mixed with streptavidin magnetic particles in a ratio of 1:1.
[0126] 2) Preparation of purified anti-cryptococcal capsular polysaccharide monoclonal antibodies labeled with acridine sulfonamide
[0127] Take 200 μg of capsular polysaccharide antibody and dilute it to 1 mg / mL with 0.1 mol / L PBS (pH=7.2) to prepare chemically labeled antibody solution;
[0128] Take 10 μL of 2 mg / mL NSP-SA-NHS (acridine sulfonyl hydrazide amine salt) and add it to the antibody solution to be chemically labeled, mix well, react at room temperature in the dark for 1 hour, then add 4 μL of 10% lysine aqueous solution, mix well, react at room temperature in the dark for 30 minutes. After the reaction, put the reaction product into a dialysis bag (exclusion MW: 8000), and dialyze it with 0.02 mol / L PBS (pH=7.2) buffer at 2-8°C overnight (dialysis was performed at 4°C in this embodiment). The product is acridine sulfonamide-labeled capsular polysaccharide monoclonal antibody.
[0129] 3) Preparation of calibrators and quality control products
[0130] Preparation method of low-value calibrator (1 ng / mL): Take capsular polysaccharide and add ultrapure water to make an aqueous solution with a concentration of 20 ng / mL. Take 5 mL of it and add 20 mL of mannitol solution, 6 mL of polyvinyl pyrrolidone (PVP), and 20 mL of newborn calf serum. Then add ultrapure water to 100 mL and mix well to obtain the low-value calibrator (1 ng / mL).
[0131] Preparation method of high-value calibrator (50ng / mL): Take capsular polysaccharide and add ultrapure water to make an aqueous solution with a concentration of 1000ng / mL, take 5mL of it and add 20mL mannitol solution, 6mL polyvinyl pyrrolidone (PVP), 20mL newborn calf serum, and then add ultrapure water to 100mL, mix well, and this is the high-value calibrator (50ng / mL).
[0132] Preparation method of low-value quality control product (0.5ng / mL): Take capsular polysaccharide and add ultrapure water to make an aqueous solution with a concentration of 10ng / mL, take 5mL of it and add 20mL mannitol solution, 6mL polyvinyl pyrrolidone (PVP), 20mL newborn calf serum, and then add ultrapure water to 100mL, mix well, and this is the low-value quality control product (0.5ng / mL).
[0133] Preparation method of high-value quality control product (50ng / mL): Take capsular polysaccharide and add ultrapure water to make an aqueous solution with a concentration of 1000ng / mL, take 5mL of it and add 20mL mannitol solution, 6mL polyvinyl pyrrolidone (PVP), 20mL newborn calf serum, and then add ultrapure water to 100mL, mix well, and this is the high-value quality control product (50ng / mL).
[0134] II) Application of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0135] The prepared cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit can use the magnetic particle chemiluminescence method to realize automatic detection on a fully automatic chemiluminescence analyzer. The specific steps are: add 50 μL of streptavidin magnetic particles and 50 μL of purified anti-cryptococcal capsular polysaccharide monoclonal antibody labeled with biotin into a reaction cup, mix well, incubate at 37°C for 15 minutes, then separate the magnetic particles under an external magnetic field, absorb the liquid in the reaction cup, and add 300 μL of cleaning solution (the cleaning solution is 20×PBS buffer, pH 7.2-7.4, working concentration 0.01M) for washing, remove the supernatant, wash repeatedly 3 times, then add 100μL of the sample to be tested to the reaction cup, mix, and incubate at 37°C for 15min; separate the magnetic particles again under an external magnetic field, remove the liquid in the reaction cup, add 300μL of cleaning solution to the reaction cup for washing, remove the supernatant, wash repeatedly 3 times, then add 100μL of acridine sulfonamide labeled purified anti-cryptococcosis capsule polysaccharide monoclonal antibody to the reaction cup, mix, and incubate at 37°C for 15min. For the third time, separate the magnetic particles under an external magnetic field, remove the liquid in the reaction cup, add 300μL of cleaning solution to the reaction cup for washing, remove the supernatant, and wash repeatedly 3 times. Add 50μL of chemiluminescence excitation liquid A and chemiluminescence excitation liquid B to the reaction cup, and immediately measure the chemiluminescence value to detect the content of cryptococcosis capsule polysaccharide in the sample to be tested.
[0136] The cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit of the present invention utilizes a sandwich method to detect cryptococcal capsular polysaccharide in a sample; a capture antibody (biotin-labeled purified anti-cryptococcal capsular polysaccharide monoclonal antibody) coupled with streptavidin magnetic microparticles, capsular polysaccharide and a detection antibody modified with a chemiluminescent group (chemiluminescent group-labeled purified anti-cryptococcal capsular polysaccharide monoclonal antibody) form a capture antibody-antigen-detection antibody immune complex; and a streptavidin-biotin (SA-Biotin) system has extremely high binding affinity; after magnetic separation and washing to remove substances not bound to the magnetic beads, an excitation liquid is added to emit light; and the content of cryptococcal capsular polysaccharide in the sample is analyzed by detecting the chemiluminescence intensity; the kit has the advantages of high sensitivity, good specificity, less interfering substances, fast detection speed, and the ability to realize machine automation operation, and is suitable for early diagnosis of clinical fungal infection.
[0137] Example 6 Anti-interference effect of cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0138] In this example, different concentrations of hydroxyethyl starch, macroglobulin, rheumatoid factor and different counts of Sporothrix, Trichosporon, and Mycobacterium tuberculosis (specific added concentrations or bacterial counts are shown in Table 3) were added to clinical samples containing 0.5 ng / mL and 5 ng / mL of capsular polysaccharide, respectively. The samples with added interference substances were again measured using the Cryptococcus capsular polysaccharide magnetic particle chemiluminescence detection kit prepared in Example 5 according to the application method in Example 5, and the interference degree of the interfering substances on the capsular polysaccharide detection was calculated. The calculation formula is as follows:
[0139] Interference degree (%) = (measured concentration of sample capsular polysaccharide after adding interfering substance - actual concentration of sample capsular polysaccharide without adding interfering substance) / actual concentration of sample capsular polysaccharide without adding interfering substance × 100%.
[0140] By calculating the interference degree of interfering substances on the detection of capsular polysaccharides, the results are shown in the following table:
[0141] Table 3 Anti-interference effect of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0142]
[0143]
[0144] It can be seen from the above table that even after adding high concentrations of interfering substances, the degree of interference is still within 10.0% when the cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit for detecting capsular polysaccharide prepared by the present invention is used. This indicates that the cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit prepared by the present invention has a strong anti-interference ability in the process of detecting clinical samples, and will not produce false positive results caused by interfering substances, and can provide more accurate detection data for clinical use.
[0145] Example 7 Sensitivity of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0146] In this example, three batches of cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kits prepared in Example 5 were used to detect samples of different concentrations and negative controls according to the application method in Example 5. When the ratio of the test results of the test samples to the test results of the negative control was greater than 2.1, the corresponding concentration was the sensitivity of the kit. The results are shown in the following table:
[0147] Table 4 Sensitivity results of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0148]
[0149] It can be seen from the above table that the sensitivity of the Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit prepared by the present invention is 0.10 ng / mL. The kit has high sensitivity and can provide more accurate detection data for clinical use.
[0150] Example 8 Stability of Cryptococcus capsular polysaccharide magnetic microparticle chemiluminescence detection kit
[0151] In this example, three batches of cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kits prepared in Example 5 were stored at 2-8° C. The kits were taken out after 0, 3, 6, 9, and 12 months, respectively. The low-value quality control product [capsular polysaccharide concentration of 0.5 ng / mL] and the high-value quality control product [capsular polysaccharide concentration of 50 ng / mL] were detected according to the application method in Example 5, and the relative deviation was calculated. The calculation formula is as follows:
[0152] Relative deviation = |(concentration value of current detection - concentration value of initial detection) / concentration value of initial detection|×100%.
[0153] The results are shown in the following table:
[0154] Table 5 Stability test results
[0155]
[0156]
[0157] It can be seen from the above table that after the kit is stored for 12 months, the deviation of the quality control product test result is less than 15%, indicating that the cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit prepared by the present invention has good stability.
[0158] Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
Claims
1. An anti-cryptococcal capsular polysaccharide monoclonal antibody, characterized in that: The anti-cryptococcal capsular polysaccharide monoclonal antibody comprises a light chain variable region determining cluster complementary region and a heavy chain variable region determining cluster complementary region; The amino acid sequence of the complementary region of the light chain variable region determining cluster is selected from the amino acid sequence of the CDRs of the following group: VL-CDR1 shown in SEQ ID NO: 1, VL-CDR2 shown in SEQ ID NO: 2, and VL-CDR3 shown in SEQ ID NO: 3; The amino acid sequence of the heavy chain variable region complementary region determining cluster is selected from the following group of CDR amino acid sequences: VH-CDR1 shown in SEQ ID NO: 4, VH-CDR2 shown in SEQ ID NO: 5 and VH-CDR3 shown in SEQ ID NO:
6.
2. The anti-cryptococcal capsular polysaccharide monoclonal antibody according to claim 1, characterized in that: The amino acid sequence of the complementary region of the light chain variable region determining cluster of the anti-cryptococcal capsular polysaccharide monoclonal antibody is SEQ ID NO: 7; the amino acid sequence of the complementary region of the heavy chain variable region determining cluster is SEQ ID NO:
8.
3. A gene encoding the anti-cryptococcal capsular polysaccharide monoclonal antibody according to claim 1 or 2, characterized in that: The nucleotide sequence of the complementary region of the light chain variable region determining cluster is SEQ ID NO:9, and the nucleotide sequence of the complementary region of the heavy chain variable region determining cluster is SEQ ID NO:
10.
4. A recombinant vector comprising the gene of the anti-cryptococcal capsular polysaccharide monoclonal antibody according to claim 3.
5. A recombinant expression cell comprising the gene of the anti-cryptococcal capsular polysaccharide monoclonal antibody according to claim 3.
6. A cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit, characterized in that: It contains the anti-cryptococcus capsular polysaccharide monoclonal antibody according to claim 1 or 2.
7. The cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit according to claim 6, characterized in that: The cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit contains the anti-cryptococcal capsular polysaccharide monoclonal antibody labeled with biotin.
8. The cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit according to claim 6 or 7, characterized in that: The cryptococcal capsular polysaccharide magnetic particle chemiluminescence detection kit also contains the anti-cryptococcal capsular polysaccharide monoclonal antibody labeled with a chemiluminescent group.
9. A method for detecting cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence, characterized in that: The method for detecting cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence is to use the cryptococcal capsular polysaccharide magnetic microparticle chemiluminescence detection kit according to any one of claims 6 to 8, and adopt the magnetic microparticle chemiluminescence method for detection.
Citation Information
Patent Citations
Anti-cryptococcal capsular polysaccharide monoclonal antibody and preparation and application of hybridoma cell strain thereof
CN109879961A
Anti-cryptococcus capsular polysaccharide monoclonal antibody, preparation of hybridoma cell strain thereof and application
CN109880805A
Collagen-localized immunomodulatory molecules and methods thereof
CN112771071A
Monoclonal antibody for resisting cryptococcus capsular polysaccharide and application thereof
CN114920837A
Anti-cryptococcus capsular polysaccharide monoclonal antibody and use thereof
WO2023245800A1
